South Korea · Delayed Price · Currency is KRW Whan In Pharm Statistics
Total Valuation
Whan In Pharm has a market cap or net worth of KRW 187.06 billion. The enterprise value is 124.02 billion.
| Market Cap | 187.06B |
| Enterprise Value | 124.02B |
Important Dates
The next estimated earnings date is Monday, July 27, 2026.
| Earnings Date | Jul 27, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
Whan In Pharm has 18.48 million shares outstanding. The number of shares has increased by 9.06% in one year.
| Current Share Class | 18.48M |
| Shares Outstanding | 18.48M |
| Shares Change (YoY) | +9.06% |
| Shares Change (QoQ) | +10.73% |
| Owned by Insiders (%) | 23.42% |
| Owned by Institutions (%) | 12.45% |
| Float | 14.15M |
Valuation Ratios
The trailing PE ratio is 10.58 and the forward PE ratio is 8.82. Whan In Pharm's PEG ratio is 0.35.
| PE Ratio | 10.58 |
| Forward PE | 8.82 |
| PS Ratio | 0.70 |
| PB Ratio | 0.44 |
| P/TBV Ratio | 0.45 |
| P/FCF Ratio | 47.81 |
| P/OCF Ratio | 30.78 |
| PEG Ratio | 0.35 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.64, with an EV/FCF ratio of 31.70.
| EV / Earnings | 7.78 |
| EV / Sales | 0.47 |
| EV / EBITDA | 4.64 |
| EV / EBIT | 7.34 |
| EV / FCF | 31.70 |
Financial Position
The company has a current ratio of 4.10, with a Debt / Equity ratio of 0.00.
| Current Ratio | 4.10 |
| Quick Ratio | 2.36 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | 0.15 |
| Interest Coverage | 550.45 |
Financial Efficiency
Return on equity (ROE) is 3.98% and return on invested capital (ROIC) is 3.95%.
| Return on Equity (ROE) | 3.98% |
| Return on Assets (ROA) | 2.35% |
| Return on Invested Capital (ROIC) | 3.95% |
| Return on Capital Employed (ROCE) | 4.03% |
| Weighted Average Cost of Capital (WACC) | 5.65% |
| Revenue Per Employee | 419.86M |
| Profits Per Employee | 25.14M |
| Employee Count | 601 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 2.01 |
Taxes
In the past 12 months, Whan In Pharm has paid 3.27 billion in taxes.
| Income Tax | 3.27B |
| Effective Tax Rate | 17.01% |
Stock Price Statistics
The stock price has decreased by -14.16% in the last 52 weeks. The beta is 0.26, so Whan In Pharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.26 |
| 52-Week Price Change | -14.16% |
| 50-Day Moving Average | 10,775.80 |
| 200-Day Moving Average | 10,949.80 |
| Relative Strength Index (RSI) | 35.75 |
| Average Volume (20 Days) | 53,637 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Whan In Pharm had revenue of KRW 266.19 billion and earned 15.94 billion in profits. Earnings per share was 956.82.
| Revenue | 266.19B |
| Gross Profit | 91.76B |
| Operating Income | 17.12B |
| Pretax Income | 19.21B |
| Net Income | 15.94B |
| EBITDA | 26.97B |
| EBIT | 17.12B |
| Earnings Per Share (EPS) | 956.82 |
Balance Sheet
The company has 63.62 billion in cash and 579.15 million in debt, with a net cash position of 63.04 billion or 3,410.41 per share.
| Cash & Cash Equivalents | 63.62B |
| Total Debt | 579.15M |
| Net Cash | 63.04B |
| Net Cash Per Share | 3,410.41 |
| Equity (Book Value) | 424.14B |
| Book Value Per Share | 22,946.53 |
| Working Capital | 175.69B |
Cash Flow
In the last 12 months, operating cash flow was 6.08 billion and capital expenditures -2.17 billion, giving a free cash flow of 3.91 billion.
| Operating Cash Flow | 6.08B |
| Capital Expenditures | -2.17B |
| Depreciation & Amortization | 9.85B |
| Net Borrowing | -538.57M |
| Free Cash Flow | 3.91B |
| FCF Per Share | 211.67 |
Margins
Gross margin is 34.47%, with operating and profit margins of 6.43% and 5.99%.
| Gross Margin | 34.47% |
| Operating Margin | 6.43% |
| Pretax Margin | 7.22% |
| Profit Margin | 5.99% |
| EBITDA Margin | 10.13% |
| EBIT Margin | 6.43% |
| FCF Margin | 1.47% |
Dividends & Yields
This stock pays an annual dividend of 300.00, which amounts to a dividend yield of 2.96%.
| Dividend Per Share | 300.00 |
| Dividend Yield | 2.96% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 28.73% |
| Buyback Yield | -9.06% |
| Shareholder Yield | -6.10% |
| Earnings Yield | 8.52% |
| FCF Yield | 2.09% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 14, 2010. It was a forward split with a ratio of 2.
| Last Split Date | Apr 14, 2010 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Whan In Pharm has an Altman Z-Score of 3.99 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.99 |
| Piotroski F-Score | 3 |